Prostate Cancer Trial, Recruiting NCT05850182 Sponsor: Oncology Institute of Southern Switzerland Condition: Prostate Cancer
Back to Prostate Cancer

Prostate Cancer Trial, Recruiting

NCT05850182
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have signed a written consent form before registering for the trial
  • People aged 18 years or older
  • People whose prostate cancer has been confirmed by biopsy or tissue testing to be a type called adenocarcinoma
  • People with prostate cancer who are currently receiving hormone-blocking therapy (ADT) alone, or hormone-blocking therapy combined with one of these medications: abiraterone, enzalutamide, apalutamide, or darolutamide
  • People whose PSA (a prostate cancer marker in the blood) has risen on two separate tests, each showing more than 25% above its lowest recorded level, with the tests taken at least three weeks apart, and with no signs of the cancer spreading on scans or physical examination
  • People whose PSA is doubling in more than 8 weeks (meaning the PSA is rising relatively slowly)
  • People whose treating doctor considers it safe and practical to continue their current cancer treatment during the trial

Who may not be able to join:

  • People currently receiving chemotherapy drugs docetaxel or cabazitaxel, radioactive treatments, or any other experimental treatments
  • People whose cancer is showing signs of spreading, either physically or on imaging scans
  • People with bone metastases (cancer that has spread to the bones) where physical exercise would not be safe
  • People with a previously confirmed diagnosis of severe osteoporosis or other bone diseases, particularly with a history of fractures
  • People with significant heart conditions, including: a heart attack within the past 6 months, uncontrolled chest pain within the past 3 months, serious heart failure, a significant history of irregular heart rhythms, or blood pressure that is too high (systolic above 170 or diastolic above 105 mmHg) at the time of screening
  • People with a significant chronic lung disease affecting breathing (confirm with trial site)
  • People with any other ongoing illness or health condition that would prevent full participation in the trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +41 91 811 84 63

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Oncology Institute of Southern Switzerland
Registry
ClinicalTrials.gov
Start date
27 November 2023
Est. completion
31 December 2026

Where this trial is recruiting

🇨🇭 Switzerland

Primary endpoints

Patient initiation rate; Patient retention rate; Adherence to prescribed training program; Adherence to prescribed dietary regimen

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov